|Description||Udenafil is an oral PDE5 inhibitor. Udenafil significantly increased cAMP and cGMP levels and were more highly distributed in the prostate than plasma. The T/P ratio of udenafil was higher than tadalafil. These findings may help in the assessment of the feasibility of using PDE5 Is to concurrently treat both LUTS and erectile dysfunction. After 12 weeks of treatment, the patients treated with udenafil showed significantly greater change from baseline in the IIEF-EF domain score compared with placebo (placebo, 0.20; 100-mg udenafil, 7.52; and 200-mg udenafil, 9.93, respectively) (P < 0.0001). udenafil significantly enhanced the rates of successful penetration (SEP Q2) and maintenance of erection (SEP Q3) (P < 0.0001).|
|Synonyms||DA-8159, DA 8159, DA8159, Udenafil, Zydena|
FR-229934 is a Type 5 cyclic nucleotide phosphodiesterase inhibitor. In Feb 2008, preclinical for Erectile dysfunction in Japan was discontinued.
An orally active selective type 5 cGMP phosphodiesterase inhibitor.
Sch59498 is a potent inhibitor of phosphodiesterase 1c (Pde1c) with antihypertensive and antiplatelet effect.
TAK-063 is a highly potent, selective, and orally active phosphodiesterase 10A (PDE10A) inhibitor. TAK-063 is currently being evaluated in clinical trials for t...
Win-62005 competitively and selectively inhibits cyclic GMP-inhibitable low Km cyclic AMP phosphodiesterase (PDE III) from rat heart and canine aorta (Kis= 25 a...
FIPI, a derivative of halopemide, is a potent and selective phospholipase D (PLD) inhibitor with IC50 values of 20 and 25 nM for PLD2 and PLD1 respectively. It ...
Dipyridamole (Persantine) is a phosphodiesterase inhibitor that blocks uptake and metabolism of adenosine by erythrocytes and vascular endothelial cells.
PDE5 inhibitor 42
PDE5 inhibitor 42 is a second-generation phosphodiesterase type 5 (PDE5) inhibitor (IC50 = 0.04 nM).